Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec 16:12:383.
doi: 10.1186/1477-7819-12-383.

Overexpression of miR-126 sensitizes osteosarcoma cells to apoptosis induced by epigallocatechin-3-gallate

Liangdong Jiang, Cheng Tao, Aiyong He, Xiaojie He  1
Affiliations

Overexpression of miR-126 sensitizes osteosarcoma cells to apoptosis induced by epigallocatechin-3-gallate

Liangdong Jiang et al. World J Surg Oncol. .

Abstract

Background: miR-126 plays an important role in the proliferation, invasion, migration, and chemotherapeutics resistance in cancer. Epigallocatechin-3-gallate (EGCG), as the major polyphenolic constituent present in green tea, is a promising anticancer agent. However, the role of miR-126 in EGCG anticancer remains unclear. Here, we investigated the effects of miR-126 and EGCG on cell viability, apoptosis, cell cycle distribution of osteosarcoma cells and the sensitization of miR-126 on osteosarcoma cells to EGCG.

Methods: The cell viability, apoptosis and cycle distribution were analyzed using MTT assay and flow cytometry.

Results: Our results showed that EGCG (0.025, 0.05, 0.1, 0.2 g/L) suppresses proliferation of osteosarcoma MG63 and U2OS cells in a concentration-dependent and time-dependent manner and the inhibitory effects of 0.05 g/L EGCG on U2OS cells were roughly equivalent to 20 μM cisplatin (DDP); miR-126 could promote apoptosis and inhibit proliferation in U2OS cells but without significant effects on cell cycle G1 phase arrest; EGCG suppressed proliferation of U2OS cells through induction of cell cycle G1 arrest and apoptotic death; overexpression of miR-126 enhanced the inhibitory effects of EGCG on proliferation in U2OS cells via promotion of apoptosis.

Conclusions: Our results demonstrate that enhanced expression of miR-126 increased the sensitivity of osteosarcoma cells to EGCG through induction of apoptosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effect of EGCG and miR-126 on proliferation in osteosarcoma cells. The relative inhibitory rate of EGCG on osteosarcoma MG63 (A) and U2OS (B) cells (C) The cell viability in U2OS cells infected with anti-miR-126, pre-miR-126, or treated with RAPA, DDP or EGCG at indicated concentration. * P <0.05 vs. indicated group; a P <0.05 vs. Con alone group; b P <0.05 vs. anti-miR-126 alone group; c P <0.05 vs. pre-miR-126 alone group. Con, control; DDP, cisplatin; EGCG, epigallocatechin-3-gallate; miR, microRNA; RAPA, rapamycin.
Figure 2
Figure 2
Effect of EGCG and miR-126 on apoptosis in osteosarcoma cells. (A) The representative images of flow cytometry analysis using Annexin V and PI staining. (B) The apoptotic rate in U2OS cells infected with anti-miR-126, pre-miR-126, or treated with RAPA, DDP or EGCG. * P <0.05 vs. indicated group; a P <0.05 vs. Con alone group; b P <0.05 vs. anti-miR-126 alone group; c P <0.05 vs. pre-miR-126 alone group. Con, control; DDP, cisplatin; EGCG, epigallocatechin-3-gallate; miR, microRNA; PI, propidium iodide; RAPA, rapamycin.
Figure 3
Figure 3
Effect of EGCG and miR-126 on cell cycle in osteosarcoma cells. (A) The representative images of flow cytometry analysis using PI staining. (B) The cell cycle distribution in U2OS cells infected with anti-miR-126, pre-miR-126, or treated with RAPA, DDP or EGCG. * P <0.05 vs. indicated group; a P <0.05 vs. Con alone group; b P <0.05 vs. anti-miR-126 alone group; c P <0.05 vs. pre-miR-126 alone group. Con, control; DDP, cisplatin; EGCG, epigallocatechin-3-gallate; miR, microRNA; PI, propidium iodide; RAPA, rapamycin.
See this image and copyright information in PMC

References

    1. Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev. 2014;40:523–532. doi: 10.1016/j.ctrv.2013.11.006. - DOI - PubMed
    1. Lambert JD, Sang S, Hong J, Yang CS. Anticancer and anti-inflammatory effects of cysteine metabolites of the green tea polyphenol, (-)-epigallocatechin-3-gallate. J Agric Food Chem. 2010;58:10016–10019. doi: 10.1021/jf102311t. - DOI - PMC - PubMed
    1. Kalaiselvi P, Rajashree K, Bharathi Priya L, Padma VV. Cytoprotective effect of epigallocatechin-3-gallate against deoxynivalenol-induced toxicity through anti-oxidative and anti-inflammatory mechanisms in HT-29 cells. Food Chem Toxicol. 2013;56:110–118. doi: 10.1016/j.fct.2013.01.042. - DOI - PubMed
    1. Cheng CW, Shieh PC, Lin YC, Chen YJ, Lin YH, Kuo DH, Liu JY, Kao JY, Kao MC, Way TD. Indoleamine 2,3-dioxygenase, an immunomodulatory protein, is suppressed by (-)-epigallocatechin-3-gallate via blocking of gamma-interferon-induced JAK-PKC-delta-STAT1 signaling in human oral cancer cells. J Agric Food Chem. 2010;58:887–894. doi: 10.1021/jf903377e. - DOI - PubMed
    1. Pae M, Wu D. Immunomodulating effects of epigallocatechin-3-gallate from green tea: mechanisms and applications. Food Funct. 2013;4:1287–1303. doi: 10.1039/c3fo60076a. - DOI - PubMed